



Executive Summary of Joint Working Outputs
Published on www.bayer.co.uk

Project Title	IMP Healthcare (Lincolnshire GP Federation) AF Screening and Diagnosis and Treatment Programme
Duration	November 2017 to June 2019
Project Partners	IMP Healthcare Limited Bayer plc
What was the issue to be addressed?	The aim was to speed up the time from identification of Atrial Fibrillation (AF) to commencing appropriate anticoagulation for a population of 50,000 people across West Lincolnshire.
What was the intervention?	The project was designed to have three separate elements of care developed. The aim was to provide a prevention-led, seamless and integrated pathway of care for the screening, diagnosis and treatment of arrhythmia and AF. Confirmation of diagnosis was achieved using portable ECG devices, 12 lead ECG and 3-day continuous ECG monitoring. Furthermore, this pilot programme was intended to allow evaluation of the process with a view to wider implementation if effective.
What were the results?	• Six Federation practices participated in the project • 4,238 patients were screened with a portable ECG device • 245 patients presented with an abnormal portable ECG traces, of whom 100% were offered a 12-lead ECG within 2 weeks • Of this group, 71 patients were offered 3-day continuous monitoring. Of those who received 3-day monitoring, 100% had their tests interpreted within two weeks • 31 patients with previously unidentified AF were diagnosed